The

 

Word

 

Is

Getting

 

Out

 

In the News

 

Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

LEXINGTON, Mass., May 29, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative andREAD MORE…

Immunexpress Strengthens Board of Directors with Key Appointments

SEATTLE, May 15, 2018 /PRNewswire/ — Immunexpress, Inc. today announced the appointment of three new members to its Board of Directors. Rolland Carlson, PhD, Tanja Dowe and KatleenREAD MORE…

PolarityTE Acquires Operating GLP/USDA Preclinical Biomedical Research Facility and Announces Caroline Garrett DVM from Johns Hopkins as Chief Veterinary Officer at Polarity

SALT LAKE CITY, May 14, 2018 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) announced the acquisition of a preclinical biomedical researchREAD MORE…

PolarityTE™ Accelerates Sales Team for Targeted Regional Release of SkinTE™

SALT LAKE CITY, May 09, 2018 (GLOBE NEWSWIRE) — PolarityTE, Inc. (Nasdaq:COOL) announced today that it is growing its commercialREAD MORE…

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

SCYTHIAN BIOSCIENCES ANNOUNCES EXTENSION OF LETTER OF INTENT

Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSX-V:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that the Company has signedREAD MORE…

PolarityTE™ Regenerates Complex, Hierarchically-Organized, Corticocancellous Bone in Preclinical Studies

PolarityTE™, Inc. (NASDAQ:COOL) announced results demonstrating that the Company’s autologous bone product in development, OsteoTETM, regenerated complex, hierarchically-organized, corticocancellous boneREAD MORE…

Athersys and Healios Extend by One Month the Period to Complete Collaboration Expansion Agreements

Athersys, Inc. (NASDAQ:ATHX) and HEALIOS K.K. (“Healios”) (TSE Mothers Code:4593) have agreed to extend the period from April 30, 2018 to May 31, 2018 to completeREAD MORE…

PROMIS NEUROSCIENCES CLOSES $7.2 MILLION PRIVATE PLACEMENT

ProMIS Neurosciences Inc. (TSX:PMN; OTCQB:ARFXF) is pleased to announce that it closed yesterday  a private placement of 19,306,668 Units at theREAD MORE…

MOTIF BIO REVIVE-2 PHASE 3 STUDY RESULTS WITH ICLAPRIM PUBLISHED IN PEER-REVIEWED JOURNAL, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the results fromREAD MORE…

PTC Therapeutics to Participate at Upcoming Investor Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health CareREAD MORE…

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2018 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarterREAD MORE…

Catalyst Pharmaceuticals Introduces New Corporate Website

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronicREAD MORE…

UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma Patients

The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (ATHX) today announced plans to conduct aREAD MORE…

Novavax Announces Closing of Public Offering

GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases,READ MORE…

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highlyREAD MORE…

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapiesREAD MORE…

LIBERTY HEALTH SCIENCES’ SALES SURGE ON EXPLOSIVE MARKET GROWTH IN EARLY 2018

Toronto, Ontario – April 11, 2018 – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company”) today announced thatREAD MORE…

Motif Bio Announces Iclaprim Abstracts for ECCMID 2018 Now Online

NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developingREAD MORE…

United Neuroscience and University of Texas Southwestern Medical Center Announce Collaboration to Evaluate Endobody Vaccine Candidates Directed at Tau Protein for the Treatment and Prevention of Alzheimer’s Disease

DUBLIN, April 11, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that it has signed a collaboration agreement with the Center for Alzheimer’sREAD MORE…

SCYTHIAN BIOSCIENCES ANNOUNCES DETAILS OF 4-FOR-1 STOCK SPLIT

TORONTO, April 10, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF)READ MORE…

PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs

SOUTH PLAINFIELD, N.J., April 9, 2018 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17,READ MORE…

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 6, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative andREAD MORE…

DALCOR PHARMACEUTICALS TO PRESENT AT BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE 2017 APRIL 27, 2017

LONDON and MONTREAL, April 27, 2017 – DalCor Pharmaceuticals today announced that senior management will present at the Bloom BurtonREAD MORE…

Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress

GAITHERSBURG, Md., April 02, 2018 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced it will present on its two lead vaccine programs atREAD MORE…

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease

SAN FRANCISCO, April 2, 2018​ – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced 12-month results fromREAD MORE…

Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies forREAD MORE…

LIBERTY HEALTH SCIENCES APPLAUDS PROTECTIONS PROVIDED BY CONGRESS FOR STATE-APPROVED MEDICAL CANNABIS LAWS

Toronto, Ontario – March 23, 2018 – Liberty Health Sciences Inc. (CSE: LHS or US OTCBB: LHSIF) (the “Company” or “Liberty”) applauds today’s passage ofREAD MORE…

Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results

Zug, Switzerland, March 22, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

BERKELEY HEIGHTS, N.J., March 21, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapiesREAD MORE…

LIBERTY HEALTH SCIENCES APPOINTS JENNIFER TIMOTHEE OLIVERAS, M.D., AS MEDICAL DIRECTOR

Toronto, Ontario – March 21, 2018 – Liberty Health Sciences Inc. (CSE: LHS or US OTCBB: LHSIF) (the “Company” or “Liberty”) is pleased to announceREAD MORE…

Athersys to Present at Needham Healthcare Conference on March 28

CLEVELAND, March 20, 2018 (GLOBE NEWSWIRE) — Athersys, Inc. (ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, willREAD MORE…

Motif Bio Update on NDA Submission for Iclaprim

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developingREAD MORE…

AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistantREAD MORE…

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update

NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused onREAD MORE…

Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results

VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, todayREAD MORE…

Novavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results

Gaithersburg, MD, March 7, 2018 — Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report itsREAD MORE…

Curis Reports Fourth Quarter and Year-End 2017 Financial Results

LEXINGTON, Mass., March 8, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovativeREAD MORE…

Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference

BERKELEY HEIGHTS, N.J., March 06, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cellREAD MORE…

Riot Blockchain Appoints Rob Chang as Chief Financial Officer

CASTLE ROCK, Colo., Feb. 28, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it hasREAD MORE…

MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers

SAN DIEGO, Feb. 28, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development ofREAD MORE…

Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine

GAITHERSBURG, Md., February 28, 2018 — Novavax, Inc., (Nasdaq:NVAX) today announced positive top-line results from its Phase 1/2 clinical trial in older adultsREAD MORE…

Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

VANCOUVER, B.C. and WARMINSTER, Pa., Feb. 22, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announcedREAD MORE…

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapiesREAD MORE…

Riot Blockchain Enters Definitive Agreement for the Acquisition of 3,800 S9 Bitcoin Miners

CASTLE ROCK, Colo., Feb. 15, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has enteredREAD MORE…

Oncobiologics Reports First Quarter Fiscal Year 2018 Results

CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) today reported financial results and business highlights for its first fiscal quarter ended DecemberREAD MORE…

Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) —  Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,READ MORE…

Auris Medical Announces Extraordinary General Meeting of Shareholders

Zug, Switzerland, February 9, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Oncobiologics Announces Term Extension Of Series A Warrants

CRANBURY, N.J., Feb. 09, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today an extension to the term for exercise of itsREAD MORE…

Arbutus Consolidates HBV Business Around Warminster, PA Site

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

Sigilon Therapeutics to Present at Upcoming Conferences

CAMBRIDGE, Mass., Feb. 8, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced thatREAD MORE…

Riot Blockchain Participates in Coinsquare Private Placement; Coinsquare Receives CAD $430 Million Post-Money Valuation

CASTLE ROCK, Colo., Feb. 8, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has investedREAD MORE…

Riot Blockchain Enters LOI to Acquire Logical Brokerage Corp

CASTLE ROCK, Colo., Feb. 7, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it hasREAD MORE…

Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine

Zug, Switzerland, February 7, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

SAN FRANCISCO, Feb. 6, 2018​ – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced toplineREAD MORE…

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

MabVax Therapeutics Closes $2.1 Million Private Placement Financing

SAN DIEGO, Feb. 6, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (the “Company”) (Nasdaq: MBVX), a clinical-stage biotechnology company focused on theREAD MORE…

PolarityTE™ Provides Business Updates on Clinical Use of SkinTE™: Regeneration of Full-Thickness Skin

SALT LAKE CITY, Feb. 05, 2018 (GLOBE NEWSWIRE) — PolarityTE, Inc. (NASDAQ:COOL), today announced that initial results from the clinicalREAD MORE…

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT PhaseREAD MORE…

Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering

Zug, Switzerland, January 29, 2018 – Auris Medical Holding AG (“Auris Medical”, NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmetREAD MORE…

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on January 16, 2018 the Compensation CommitteeREAD MORE…

Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel’s leading commercial partner for innovativeREAD MORE…

Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference

BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of theREAD MORE…

Gaumard Unveils World’s Most Advanced Pediatric Simulator

MIAMI, Jan. 25, 2018 — A young child may have trouble explaining medical symptoms – yet a quick look at hisREAD MORE…

ProMIS Neurosciences Issues Response to Recent Market Activity

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017 /PRNewswire/ – At the request of IIROC (“Investment Industry Regulatory Organization of Canada“), ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF)READ MORE…

Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology

SAN FRANCISCO, Jan. 22, 2018 ​– Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced the appointment ofREAD MORE…

Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections

SAN DIEGO, Jan. 18, 2018 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needsREAD MORE…

Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

LEXINGTON, Mass., Jan. 17, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovativeREAD MORE…

Gaumard Unveils World’s Most Advanced Pediatric Simulator at IMSH ’18

MIAMI, Jan. 12, 2018 /PRNewswire/ — A young child may have trouble explaining medical symptoms – yet a quick look at hisREAD MORE…

Riot Blockchain Establishes Digital Green Energy Corp as New Subsidiary

CASTLE ROCK, Colo., Jan. 9, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has establishedREAD MORE…

Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

BERKELEY HEIGHTS, N.J., Jan. 09, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) reviewed itsREAD MORE…

PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities

PTC Therapeutics, Inc. (PTCT) today provided a corporate update, which will be detailed as part of the company’s presentation atREAD MORE…

Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged Living Therapeutics, todayREAD MORE…

Auris Medical Provides Update on AM-111 Development Program

Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, todayREAD MORE…